Home NDC 0002-3977 RETEVMO
Product NDC 0002-3977
11-digit product format 000023977
Labeler code 0002
Product ID 0002-3977_7481a510-805c-4f99-b6ae-7b44e70f5f55
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name selpercatinib
Dosage form CAPSULE
Route ORAL
Labeler Eli Lilly and Company
Application NDA213246
Marketing category NDA
Marketing start 2020-05-08
Substance SELPERCATINIB
Active strength 40 mg/1
Pharmacologic classes Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A Inhibitors [MoA], Kinase Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA], Rearranged during Transfection (RET) Inhibitors [MoA]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 43 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N213246-001 RETEVMO SELPERCATINIB 40MG CAPSULE / ORAL RLD 2020-05-08 N213246-002 RETEVMO SELPERCATINIB 80MG CAPSULE / ORAL RLD, RS 2020-05-08
Orange Book patents# Current patent rows page 1 of 1 · 54 matching rows.
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 44 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 2 · 78 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-09-14 22:38:34 2026-08 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 84e616aacf4f…2026-08-18 06:07:40 2026-07 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 8072bd15b7f6…2024-05-31 18:47 UTC 2024-05 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 5c6f7cd8ea54…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 5d02ea3f76ae…2022-04-08 23:34 UTC 2022-04 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 4b0b4de00fa7…2022-04-04 05:41 UTC 2022-04 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 4b0b4de00fa7…2022-03-09 01:35 UTC 2022-03 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 bb7c543d1eb4…2022-03-09 01:35 UTC 2022-03 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 bb7c543d1eb4…
Observed Orange Book patent history# Patent history page 1 of 51 · 2,002 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-09-14 22:38:34 2026-08 N213246-001 10112942 2037-10-10 Drug substance, Drug product 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10137124 2037-10-10 U-3450 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10137124 2037-10-10 U-3949 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10137124 2037-10-10 U-3950 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10137124 2037-10-10 U-3951 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10172851 2037-10-10 U-3450 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10172851 2037-10-10 U-3949 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10172851 2037-10-10 U-3950 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10172851 2037-10-10 U-3951 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10112942*PED 2038-04-10 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10137124*PED 2038-04-10 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10172851*PED 2038-04-10 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10584124 2038-10-10 U-3450 Drug substance 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10584124 2038-10-10 U-3949 Drug substance 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10584124 2038-10-10 U-3950 Drug substance 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10584124 2038-10-10 U-3951 Drug substance 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10786489 2038-10-10 U-3450 Drug product 2020-10-26 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10786489 2038-10-10 U-3949 Drug product 2020-10-26 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10786489 2038-10-10 U-3951 Drug product 2020-10-26 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10786489 2038-10-10 U-3950 Drug product 2020-10-26 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 12138250 2038-10-10 U-3949 2024-12-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 12138250 2038-10-10 U-3951 2024-12-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 12138250 2038-10-10 U-3950 2024-12-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 12138250 2038-10-10 U-3450 2024-12-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10584124*PED 2039-04-10 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 10786489*PED 2039-04-10 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-001 12138250*PED 2039-04-10 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 10112942 2037-10-10 Drug substance, Drug product 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 10137124 2037-10-10 U-3450 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 10137124 2037-10-10 U-3949 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 10137124 2037-10-10 U-3951 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 10137124 2037-10-10 U-3950 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 10172851 2037-10-10 U-3951 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 10172851 2037-10-10 U-3949 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 10172851 2037-10-10 U-3950 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 10172851 2037-10-10 U-3450 2020-06-05 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 10112942*PED 2038-04-10 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 10137124*PED 2038-04-10 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 10172851*PED 2038-04-10 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 10584124 2038-10-10 U-3450 Drug substance 2020-06-05 84e616aacf4f…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 17 · 664 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base RETEVMO
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength SELPERCATINIB 40 mg/1
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 0002-3977-60 RETEVMO 60 in 1 BOTTLE CAPSULE 60 22
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 0002-3977 RETEVMO (SELPERCATINIB) CAPSULE RETEVMO (SELPERCATINIB) TABLET, COATED [ELI LILLY AND COMPANY] 18 Current NDC, Legacy NDC, 1 package rows 20250103_7fa848ba-a59c-4144-9f52-64d090f4d828.zip
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Marketing end Sample Exclude flag Status 0002-3977-60 00002397760 60 CAPSULE in 1 BOTTLE (0002-3977-60) 60 capsule 2020-05-08 0000-00-00 No No Current